Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001313666 | SCV001504170 | uncertain significance | Nemaline myopathy 8 | 2022-09-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1014870). This variant has not been reported in the literature in individuals affected with KLHL40-related conditions. This variant is present in population databases (rs780261738, gnomAD 0.01%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 539 of the KLHL40 protein (p.Pro539Leu). |
Ambry Genetics | RCV002545062 | SCV003709843 | uncertain significance | Inborn genetic diseases | 2022-10-03 | criteria provided, single submitter | clinical testing | The c.1616C>T (p.P539L) alteration is located in exon 5 (coding exon 5) of the KLHL40 gene. This alteration results from a C to T substitution at nucleotide position 1616, causing the proline (P) at amino acid position 539 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |